Combination chemotherapy and high-dose cyclophosphamide intensification for poor prognosis breast cancer: A Southwest Oncology Group study

G. K. Ellis, S. Green, S. Schulman, B. L. Tranum, R. S. Goldberg, Robert B Livingston

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Thirty-seven patients with poor prognosis, metastatic breast cancer were treated with 5-fluorouracil, vinblastine and Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH) (FUVA) induction chemotherapy. All 26 patients (74%) with responsive or stable disease after induction chemotherapy received intensification with high-dose cyclophosphamide (120 mg/kg). Continued responders received additional FUVA as consolidation. The response rate to induction therapy was 54% (with complete response [CR] in 11%). With intensification, three patients (11%) showed improved response (partial response [PR] in one, PR to complete response [CR] in two); however, six patients (23%) progressed within 2 months of cyclophosphamide intensification, three within 1 month. The overall response rate to all three phases of the study was 69%, with CR in 23%. The median survival of all patients entered in this study was 15 months. For cyclophosphamide intensification, major toxicity consisted of leukopenia with fever requiring broad-spectrum antibiotics in 27%. The authors conclude that a single cycle of high-dose cyclophosphamide intensification in metastatic breast cancer does not result in significantly improved responses or prolonged survival.

Original languageEnglish (US)
Pages (from-to)2409-2415
Number of pages7
JournalCancer
Volume64
Issue number12
DOIs
StatePublished - 1989
Externally publishedYes

Fingerprint

Combination Drug Therapy
Cyclophosphamide
Breast Neoplasms
Induction Chemotherapy
Doxorubicin
Survival
Vinblastine
Leukopenia
Fluorouracil
Fever
Anti-Bacterial Agents
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Combination chemotherapy and high-dose cyclophosphamide intensification for poor prognosis breast cancer : A Southwest Oncology Group study. / Ellis, G. K.; Green, S.; Schulman, S.; Tranum, B. L.; Goldberg, R. S.; Livingston, Robert B.

In: Cancer, Vol. 64, No. 12, 1989, p. 2409-2415.

Research output: Contribution to journalArticle

Ellis, G. K. ; Green, S. ; Schulman, S. ; Tranum, B. L. ; Goldberg, R. S. ; Livingston, Robert B. / Combination chemotherapy and high-dose cyclophosphamide intensification for poor prognosis breast cancer : A Southwest Oncology Group study. In: Cancer. 1989 ; Vol. 64, No. 12. pp. 2409-2415.
@article{45522d286664488a92a23c1e419e4a70,
title = "Combination chemotherapy and high-dose cyclophosphamide intensification for poor prognosis breast cancer: A Southwest Oncology Group study",
abstract = "Thirty-seven patients with poor prognosis, metastatic breast cancer were treated with 5-fluorouracil, vinblastine and Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH) (FUVA) induction chemotherapy. All 26 patients (74{\%}) with responsive or stable disease after induction chemotherapy received intensification with high-dose cyclophosphamide (120 mg/kg). Continued responders received additional FUVA as consolidation. The response rate to induction therapy was 54{\%} (with complete response [CR] in 11{\%}). With intensification, three patients (11{\%}) showed improved response (partial response [PR] in one, PR to complete response [CR] in two); however, six patients (23{\%}) progressed within 2 months of cyclophosphamide intensification, three within 1 month. The overall response rate to all three phases of the study was 69{\%}, with CR in 23{\%}. The median survival of all patients entered in this study was 15 months. For cyclophosphamide intensification, major toxicity consisted of leukopenia with fever requiring broad-spectrum antibiotics in 27{\%}. The authors conclude that a single cycle of high-dose cyclophosphamide intensification in metastatic breast cancer does not result in significantly improved responses or prolonged survival.",
author = "Ellis, {G. K.} and S. Green and S. Schulman and Tranum, {B. L.} and Goldberg, {R. S.} and Livingston, {Robert B}",
year = "1989",
doi = "10.1002/1097-0142(19891215)64:12<2409::AID-CNCR2820641202>3.0.CO;2-T",
language = "English (US)",
volume = "64",
pages = "2409--2415",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Combination chemotherapy and high-dose cyclophosphamide intensification for poor prognosis breast cancer

T2 - A Southwest Oncology Group study

AU - Ellis, G. K.

AU - Green, S.

AU - Schulman, S.

AU - Tranum, B. L.

AU - Goldberg, R. S.

AU - Livingston, Robert B

PY - 1989

Y1 - 1989

N2 - Thirty-seven patients with poor prognosis, metastatic breast cancer were treated with 5-fluorouracil, vinblastine and Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH) (FUVA) induction chemotherapy. All 26 patients (74%) with responsive or stable disease after induction chemotherapy received intensification with high-dose cyclophosphamide (120 mg/kg). Continued responders received additional FUVA as consolidation. The response rate to induction therapy was 54% (with complete response [CR] in 11%). With intensification, three patients (11%) showed improved response (partial response [PR] in one, PR to complete response [CR] in two); however, six patients (23%) progressed within 2 months of cyclophosphamide intensification, three within 1 month. The overall response rate to all three phases of the study was 69%, with CR in 23%. The median survival of all patients entered in this study was 15 months. For cyclophosphamide intensification, major toxicity consisted of leukopenia with fever requiring broad-spectrum antibiotics in 27%. The authors conclude that a single cycle of high-dose cyclophosphamide intensification in metastatic breast cancer does not result in significantly improved responses or prolonged survival.

AB - Thirty-seven patients with poor prognosis, metastatic breast cancer were treated with 5-fluorouracil, vinblastine and Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH) (FUVA) induction chemotherapy. All 26 patients (74%) with responsive or stable disease after induction chemotherapy received intensification with high-dose cyclophosphamide (120 mg/kg). Continued responders received additional FUVA as consolidation. The response rate to induction therapy was 54% (with complete response [CR] in 11%). With intensification, three patients (11%) showed improved response (partial response [PR] in one, PR to complete response [CR] in two); however, six patients (23%) progressed within 2 months of cyclophosphamide intensification, three within 1 month. The overall response rate to all three phases of the study was 69%, with CR in 23%. The median survival of all patients entered in this study was 15 months. For cyclophosphamide intensification, major toxicity consisted of leukopenia with fever requiring broad-spectrum antibiotics in 27%. The authors conclude that a single cycle of high-dose cyclophosphamide intensification in metastatic breast cancer does not result in significantly improved responses or prolonged survival.

UR - http://www.scopus.com/inward/record.url?scp=0024851971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024851971&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19891215)64:12<2409::AID-CNCR2820641202>3.0.CO;2-T

DO - 10.1002/1097-0142(19891215)64:12<2409::AID-CNCR2820641202>3.0.CO;2-T

M3 - Article

C2 - 2684382

AN - SCOPUS:0024851971

VL - 64

SP - 2409

EP - 2415

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -